Glycom's €50m HMO manufacturing site in Esbjerg, Denmark. © Glycom A/S

Royal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2′-fucosyl lactose, Danish Glycom A/S.

Immatics Biotechnologies has labs in Tübingen, Munich and Houston, US. © Immatics Biotechnologies GmbH

US-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.

Univercells SA

Univercells S.A. cashes in up to €50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.

© CDC

Shortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.

Dublin headquarters of Jazz Pharmaceuticals plc. ©
PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer).
A pancreatic islet from a mouse in a typical position, close to a blood vessel; insulin in red, nuclei in blue. Generated in the Solimena lab, Paul Langerhans Institute Dresden © Jakob Suckale

Using a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas. 

© Nature_Blossom/Pixabay.com

Researchers report that JAK inhibitors – a class of approved anti-inflammatory drugs – prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.

© 3D Animation Production Company/Pixabay.com

Mereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.

© Stilla Technologies

French Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing.

© BIH

Targeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".